Stellate Ganglion Block on Gastroesophageal Reflux Disease

Launched by COPKA SONPASHAN · Mar 19, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether a procedure called stellate ganglion block can help improve symptoms of gastroesophageal reflux disease (GERD) when combined with rehabilitation training. GERD is a condition where stomach acid frequently flows back into the esophagus, causing discomfort. The study will randomly assign participants into two groups: one will receive the stellate ganglion block treatment in addition to rehabilitation, while the other group will only receive rehabilitation. Over a period of 20 days, researchers will compare different questionnaires and tests to see if the treatment makes a positive difference in managing GERD symptoms.

To participate in this trial, individuals must be between 18 and 80 years old and have a diagnosis of GERD confirmed by a specialist. They need to be able to tolerate certain neck movements and have stable health conditions. However, people with specific health issues, such as peptic ulcers or a history of gastric cancer, cannot join the study. This trial aims to gather important information that could help improve treatment options for those suffering from GERD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gastroesophageal Reflux Disease diagnosis after determination of acid reflux by gastroenterologist, with upper endoscopy and/or impedance-pHmetry, which confirmed esophagitis and/or hiatal hernia.
• • aged between 18 and 80 years old.
• • subjects who tolerate cervical movements in sitting position.
• • stable vital signs.
• • normal consciousness
• Exclusion Criteria:
• • contraindications for stellate ganglion block.
• • peptic ulcer.
• • previous or present gastric cancer.
• • previous gastric surgery.
• • recent fractures or cervical trauma.